- ISIN
- US1511901050
- CUSIP
- 151190105
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Aug 8, 2019
Highlights
- EPS (TTM)
- -$3.20
- Total Revenue (TTM)
- $40.58M
- Gross Profit (TTM)
- $22.42M
- EBITDA (TTM)
- -$63.56M
- Year Range
- $0.71 - $4.35
- Target Price
- $3.00
- ROA (TTM)
- -75.14%
- ROE (TTM)
- 211.88%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CELU Performance Chart
Celularity Inc. (CELU) is down 4.5% since the beginning of the year. At $1 per share, CELU is trading 75.6% below its 52-week high of $4. Investors who bought $1,000 worth of CELU shares 5 years ago would now be looking at an investment worth $10.
Loading charts...
Returns By Period
Celularity Inc. (CELU) has returned -4.50% so far this year and -52.68% over the past 12 months.
Celularity Inc.
- 1D
- -0.93%
- 1M
- 10.76%
- YTD
- -4.50%
- 6M
- -47.52%
- 1Y
- -52.68%
- 3Y*
- -46.86%
- 5Y*
- -59.85%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.25%
- YTD
- 11.16%
- 6M
- 11.43%
- 1Y
- 28.20%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
CELU Monthly Returns History
Based on dividend-adjusted daily data since Aug 8, 2019, CELU's average daily return is -0.06%, while the average monthly return is -2.33%.
Historically, 45% of months were positive and 55% were negative. The best month was Jul 2025 with a return of +67.4%, while the worst month was Jun 2022 at -63.1%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.
On a daily basis, CELU closed higher 42% of trading days. The best single day was Nov 7, 2024 with a return of +113.1%, while the worst single day was Nov 14, 2024 at -36.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 9.91% | 0.82% | 8.13% | -29.75% | 8.10% | 4.95% | -4.50% | ||||||
| 2025 | -1.44% | -43.41% | 49.14% | -13.87% | 41.61% | -7.11% | 67.35% | 20.12% | -47.46% | -5.80% | 2.56% | -44.50% | -46.63% |
| 2024 | 53.60% | -5.79% | 46.09% | -42.07% | 2.64% | 0.64% | 0.64% | -2.22% | -3.57% | -53.54% | 47.83% | 1.96% | -15.93% |
| 2023 | -34.88% | -18.34% | -9.66% | -4.71% | 28.76% | -29.94% | -23.78% | -20.20% | -31.45% | -1.40% | -2.74% | 16.15% | -80.82% |
| 2022 | -12.11% | 59.56% | 21.31% | 34.21% | -21.13% | -63.12% | -11.47% | -9.97% | -14.76% | 0.87% | -26.61% | -24.56% | -74.80% |
| 2021 | -7.18% | -0.98% | -0.30% | 0.30% | 0.20% | 0.49% | -13.56% | -3.98% | -16.21% | -4.66% | -4.59% | -20.50% | -53.45% |
Benchmark Metrics
Celularity Inc. has an annualized alpha of -24.64%, beta of 0.72, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since August 13, 2019.
- This stock participated in 212.00% of S&P 500 Index downside but only -12.39% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -24.64%
- Beta
- 0.72
- R²
- 0.02
- Upside Capture
- -12.39%
- Downside Capture
- 212.00%
Return for Risk
Risk / Return Rank
CELU ranks 20 for risk / return — in the bottom 20% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Celularity Inc. (CELU) and compare them to S&P 500 Index.
| CELU | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.53 | 2.39 | -2.92 |
Sortino ratioReturn per unit of downside risk | -0.38 | 3.25 | -3.64 |
Omega ratioGain probability vs. loss probability | 0.95 | 1.43 | -0.48 |
Calmar ratioReturn relative to maximum drawdown | -0.65 | 3.11 | -3.76 |
Martin ratioReturn relative to average drawdown | -0.93 | 14.38 | -15.32 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Celularity Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Celularity Inc. was 99.40%, occurring on May 11, 2026. The portfolio has not yet recovered.
The current Celularity Inc. drawdown is 99.18%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.40%May 2026 | 4y 13d | — | 4y 1moApr 2022 - now |
Bear market2022 | -68.64%Jan 2022 | 6mo 2d | 3mo 2d | 9mo 4dJul 2021 - Apr 2022 |
2021 bear market2021 | -33.44%Jul 2021 | 6mo 23d | 4d | 6mo 27dDec 2020 - Jul 2021 |
Bear market2022 | -7.75%Apr 2022 | 4d | 3d | 7dApr 2022 - Apr 2022 |
COVID crash2020 | -6.36%Mar 2020 | 29d | 3mo 3d | 4mo 2dFeb 2020 - Jun 2020 |
Drawdown Indicators
| CELU | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.40% | -56.78% | -42.62% |
Max Drawdown (1Y)Largest decline over 1 year | -81.45% | -9.10% | -72.35% |
Max Drawdown (3Y)Largest decline over 3 years | -90.53% | -18.90% | -71.63% |
Max Drawdown (5Y)Largest decline over 5 years | -99.40% | -25.43% | -73.97% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.18% | 0.00% | -99.18% |
Average DrawdownAverage peak-to-trough decline | -62.89% | -10.72% | -52.17% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 56.43% | 1.97% | +54.46% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Celularity Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Celularity Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CELU relative to other companies in the Biotechnology industry. Currently, CELU has a P/S ratio of 0.7. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CELU
Add Celularity Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CELU